Outcomes after sublobar resection versus lobectomy in non-small cell carcinoma in situ.
Perez Holguin RA, Olecki EJ, Wong WG, Stahl KA, Go PH, Taylor MD, Reed MF, Shen C.
J Thorac Cardiovasc Surg. 2023 Mar;165(3):853-861.e3. doi: 10.1016/j.jtcvs.2022.05.032. Epub 2022 Jun 1.
Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer.
Zhang S, Wang W, Xu C, Zhang Y, Cai X, Wang Q, Song Z, Li Z, Yu J, Zhong W, Wang Z, Liu J, Liu A, Li W, Zhan P, Liu H, Lv T, Miao L, Min L, Lin G, Huang L, Yuan J, Jiang Z, Pu X, Rao C, Lv D, Yu Z, Li X, Tang C, Zhou C, Zhang J, Guo H, Chu Q, Meng R, Liu X, Wu J, Zhou J, Zhu Z, Pan W, Dong X, Pang F, Wang K, Yao C, Lin G, Li S, Yang Z, Luo J, Jia H, Nie X, Wang L, Zhu Y, Hu X, Xie Y, Lin X, Cai J, Xia Y, Feng H, Wang L, Du Y, Yao W, Shi X, Niu X, Yuan D, Yao Y, Kang J, Zhang J, Zhang C, Gao W, Huang J, Zhang Y, Sun P, Wang H, Ye M, Wang D, Wang Z, Wan B, Lv D, Yu G, Shi L, Xia Y, Gao F, Zhang X, Xu T, Zhou W, Wang H, Liu Z, Yang N, Wu L, Wang Q, Wang G, Hong Z, Wang J, Fang M, Fang Y, Zhang Y, Song Y, Ma S, Fang W, Lu Y.
Thorac Cancer. 2023 Jan;14(1):91-104. doi: 10.1111/1759-7714.14743. Epub 2022 Nov 28.
LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway.
He Y, Jiang X, Duan L, Xiong Q, Yuan Y, Liu P, Jiang L, Shen Q, Zhao S, Yang C, Chen Y.
Mol Cancer. 2021 Dec 2;20(1):156. doi: 10.1186/s12943-021-01469-6.
Outcome of bronchial carcinoma in situ.
Venmans BJ, van Boxem TJ, Smit EF, Postmus PE, Sutedja TG.
Chest. 2000 Jun;117(6):1572-6. doi: 10.1378/chest.117.6.1572.
Different In Situ Immune Patterns between Primary Tumor and Lymph Node in Non-Small-Cell Lung Cancer: Potential Impact on Neoadjuvant Immunotherapy.
Ye ZH, Long H, Zhao ZR.
J Immunol Res. 2022 Apr 28;2022:8513747. doi: 10.1155/2022/8513747. eCollection 2022.
Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ.
Talcott WJ, Miccio JA, Park HS, White AA, Kozono DE, Singer L, Sands JM, Sholl LM, Detterbeck FC, Mak RH, Decker RH, Kann BH.
Lung Cancer. 2021 Jul;157:17-20. doi: 10.1016/j.lungcan.2021.05.028. Epub 2021 May 26.
Multiplexed fluorescence in situ hybridization-based detection of circulating tumor cells: A novel liquid-based technology to facilitate accurate and early identification of non-small cell lung cancer patients.
Zhu Y, Lowe AC.
Cancer Cytopathol. 2020 Aug;128(8):518-519. doi: 10.1002/cncy.22277. Epub 2020 Apr 22.
Pulmonary preinvasive neoplasia.
Kerr KM.
J Clin Pathol. 2001 Apr;54(4):257-71. doi: 10.1136/jcp.54.4.257.
The natural history of carcinoma in situ involving bronchial resection margins.
Pasic A, Grünberg K, Mooi WJ, Paul MA, Postmus PE, Sutedja TG.
Chest. 2005 Sep;128(3):1736-41. doi: 10.1378/chest.128.3.1736.
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
Wu YL, Yang JC, Kim DW, Lu S, Zhou J, Seto T, Yang JJ, Yamamoto N, Ahn MJ, Takahashi T, Yamanaka T, Kemner A, Roychowdhury D, Paolini J, Usari T, Wilner KD, Goto K.
J Clin Oncol. 2018 May 10;36(14):1405-1411. doi: 10.1200/JCO.2017.75.5587. Epub 2018 Mar 29.
